Search

Your search keyword '"Di Cesare, Antonella"' showing total 131 results
Start Over Author "Di Cesare, Antonella"
131 results on '"Di Cesare, Antonella"'

4. Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation

Author

MANZO MARGIOTTA, Flavia, primary, MICHELUCCI, Alessandra, additional, CAPALBO, Eugenio, additional, RICCERI, Federica, additional, ROSI, Elia, additional, ROSSARI, Susanna, additional, MAGNANO, Michela, additional, SAVARESE, Imma, additional, MILANESI, Nicola, additional, SIMONI, Barbara, additional, ROMANELLI, Marco, additional, RUBEGNI, Pietro, additional, DI CESARE, Antonella, additional, PANDURI, Salvatore, additional, PESCITELLI, Leonardo, additional, TROVATO, Emanuele, additional, and PRIGNANO, Francesca, additional

Published
2023
Full Text
View/download PDF

8. Real‐life effectiveness of Risankizumab according to body mass index: results of an Italian multicenter retrospective study

Author

Dragotto, Martina, primary, Capalbo, Eugenio, additional, Cartocci, Alessandra, additional, Manzo Margiotta, Flavia, additional, Michelucci, Alessandra, additional, Rosi, Elia, additional, Ricceri, Federica, additional, Simoni, Barbara, additional, Savarese, Imma, additional, Milanesi, Nicola, additional, Rossari, Susanna, additional, Magnano, Michela, additional, Romanelli, Marco, additional, Rubegni, Pietro, additional, Prignano, Francesca, additional, Di Cesare, Antonella, additional, Panduri, Salvatore, additional, Pescitelli, Leonardo, additional, and Trovato, Emanuele, additional

Published
2023
Full Text
View/download PDF

10. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics

Author

PRIGNANO, Francesca, primary, PESCITELLI, Leonardo, additional, TROVATO, Emanuele, additional, DI CESARE, Antonella, additional, CUCCIA, Aldo, additional, MAZZATENTA, Carlo, additional, PELLEGRINO, Michele, additional, MARSILI, Franco, additional, CASTELLI, Antonio, additional, BRANDINI, Luca, additional, NICCOLI, Maria C., additional, TAVITI, Franca, additional, RICCERI, Federica, additional, PANDURI, Salvatore, additional, BUGGIANI, Gionata, additional, GHILARDI, Alberto, additional, RUBEGNI, Pietro, additional, ROMANELLI, Marco, additional, and PIMPINELLI, Nicola, additional

Published
2023
Full Text
View/download PDF

17. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study

Author

Galluzzo, Marco, primary, Talamonti, Marina, additional, Atzori, Laura, additional, Bardazzi, Federico, additional, Campanati, Anna, additional, Di Cesare, Antonella, additional, Diotallevi, Federico, additional, Flori, Maria Laura, additional, Mugheddu, Cristina, additional, Offidani, Annamaria, additional, Piaserico, Stefano, additional, Russo, Filomena, additional, Sacchelli, Lidia, additional, Bianchi, Luca, additional, and Prignano, Francesca, additional

Published
2022
Full Text
View/download PDF

26. Italian Guidelines in diagnosis and treatment of alopecia areata

Author

Rossi, Alfredo, primary, Muscianese, Marta, additional, Piraccini, Bianca M., additional, Starace, Michela, additional, Carlesimo, Marta, additional, Mandel, Victor D., additional, Alessandrini, Aurora, additional, Calvieri, Stefano, additional, Caro, Gemma, additional, D'arino, Andrea, additional, Federico, Alessandro, additional, Magri, Francesca, additional, Pigliacelli, Flavia, additional, Amendolagine, Graziana, additional, Annunziata, Maria C., additional, Arisi, Maria C., additional, Astorino, Stefano, additional, Babino, Graziella, additional, Bardazzi, Federico, additional, Barruscotti, Stefania, additional, Belloni Fortina, Anna, additional, Borghi, Alessandro, additional, Bruni, Francesca, additional, Caccavale, Stefano, additional, Calzavara-Pinton, Piergiacomo, additional, Cameli, Norma, additional, Cardone, Michele, additional, Carugno, Andrea, additional, Coppola, Rosa, additional, Dattola, Annunziata, additional, De Felici Del Giudice, Maria B., additional, Di Cesare, Antonella, additional, Dika, Emi, additional, Di Nunno, Donato, additional, D'ovidio, Roberto, additional, Fabbrocini, Gabriella, additional, Feliciani, Claudio, additional, Fulgione, Elisabetta, additional, Galluzzo, Marco, additional, Garcovich, Simone, additional, Garelli, Valentina, additional, Guerriero, Cristina, additional, Hansel, Katharina, additional, La Placa, Michelangelo, additional, Lacarrubba, Francesco, additional, Lora, Viviana, additional, Marinello, Elena, additional, Megna, Matteo, additional, Micali, Giuseppe, additional, Misciali, Cosimo, additional, Monari, Paola, additional, Monfrecola, Giuseppe, additional, Neri, Iria, additional, Offidani, Annamaria, additional, Orlando, Gloria, additional, Papini, Manuela, additional, Patrizi, Annalisa, additional, Piaserico, Stefano, additional, Rivetti, Niccolò, additional, Simonetti, Oriana, additional, Stan, Teodora R., additional, Stingeni, Luca, additional, Talamonti, Marina, additional, Tassone, Francesco, additional, Villa, Lucia, additional, Vincenzi, Colombina, additional, and Fortuna, Maria C., additional

Published
2019
Full Text
View/download PDF

29. Intellectual Disability and Hidradenitis Suppurativa.

Author

Rosi, Elia, Fastame, Maria Thais, Pescitelli, Leonardo, Di Cesare, Antonella, Ricceri, Federica, Pimpinelli, Nicola, Prignano, Francesca, Fastame, Maria Thais, and Di Cesare, Antonella

Subjects
HIDRADENITIS suppurativa, INTELLECTUAL disabilities, CENTRAL nervous system
Abstract

Keywords: Hidradenitis suppurativa; Intellectual disability; Comorbidities EN Hidradenitis suppurativa Intellectual disability Comorbidities 386 388 3 05/08/21 20210501 NES 210501 Dear Editor, Hidradenitis suppurativa (HS) is a chronic, inflammatory disorder that affects apocrine gland-bearing skin clinically characterized by recurrent painful deep-seated nodules, abscesses, sinus tracts, bridge scars and tombstone open comedones [[1]]. Demographic and clinical characteristics of HS patients Seven patients out of 112 (6.2%) had concomitant HS and ID. This finding is in line with that of other authors [[6]] who found a younger age of HS onset in patients with Down syndrome (DS), the most frequent genetic cause of ID, compared to those with HS only (14.9 vs. 23.3 years [[6]] and 14.3 vs. 23.4 years [[7]]). [Extracted from the article]

Published
2021
Full Text
View/download PDF

32. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments

Author

Pellegrini, Cristina, Orlandi, Augusto, Costanza, Gaetana, Di Stefani, Alessandro, Piccioni, Antonella, Di Cesare, Antonella, Chiricozzi, Andrea, Ferlosio, Amedeo, Peris, Ketty, Fargnoli, Maria Concetta, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), Peris, Ketty (ORCID:0000-0002-5237-0463), Pellegrini, Cristina, Orlandi, Augusto, Costanza, Gaetana, Di Stefani, Alessandro, Piccioni, Antonella, Di Cesare, Antonella, Chiricozzi, Andrea, Ferlosio, Amedeo, Peris, Ketty, Fargnoli, Maria Concetta, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Several immune-related markers have been implicated in basal cell carcinoma (BCC) pathogenesis. The BCC inflammatory infiltrate is dominated by Th2 cytokines, suggesting a specific state of immunosuppression. In contrast, regressing BCC are characterized by a Th1 immune response with IFN-Î3 promoting a tumor suppressive activity. IL-23/Th17-related cytokines, as interleukin (IL)-17, IL-23 and IL-22, play a significant role in cutaneous inflammatory diseases, but their involvement in skin carcinogenesis is controversial and is poorly investigated in BCC. In this study we investigated the expression of IFN-Î3, IL-17, IL-23 and IL-22 cytokines in BCC at the protein and mRNA level and their modulation during imiquimod (IMQ) treatment or photodynamic therapy (PDT). IFN-Î3, IL-17, IL-23 and IL-22 levels were evaluated by immunohistochemistry and quantitative Real Time PCR in 41 histopatho-logically-proven BCCs (28 superficial and 13 nodular) from 39 patients. All BCC samples were analyzed at baseline and 19 of 41 also during medical treatment (9 with IMQ 5% cream and 10 with MAL-PDT). Association between cytokines expression and clinico-pathological variables was evaluated. Higher levels of IFN-Î3, IL-17, IL-23 and IL-22 were found in BCCs, mainly in the peritumoral infiltrate, compared to normal skin, with the expression being correlated to the severity of the inflammatory infiltrate. IFN-Î3 production was higher in superficial BCCs compared to nodular BCCs, while IL-17 was increased in nodular BCCs. A significant correlation was found between IFN-Î3 and IL-17 expression with both cytokines expressed by CD4+ and CD8+ T-cells. An increase of all cytokines occurred during the inflammatory phase induced by IMQ and at the early time point of PDT treatment, with significant evidence for IFN-Î3, IL-23, and IL-22. Our results confirm the role of IFN-Î3 and support the involvement of IL-23/Th17-related cytokines in BCC pathogenesis and in the inflammatory response during

Published
2017

37. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients

Author

Saraceno, Rosita, primary, Camplone, Germana, additional, D'Agostino, Magda, additional, De Simone, Clara, additional, Di Cesare, Antonella, additional, Filosa, Giorgio, additional, Frascione, Pasquale, additional, Gabellini, Massimo, additional, Lunghi, Franco, additional, Mazzotta, Annamaria, additional, Peris, Ketty, additional, Scotto Di Luzio, Genoveffa, additional, Calvieri, Stefano, additional, Simonacci, Marco, additional, and Chimenti, Sergio, additional

Published
2013
Full Text
View/download PDF

41. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans

Author

Di Meglio, Paola, primary, Di Cesare, Antonella, additional, Laggner, Ute, additional, Chu, Chung-Ching, additional, Napolitano, Luca, additional, Villanova, Federica, additional, Tosi, Isabella, additional, Capon, Francesca, additional, Trembath, Richard C., additional, Peris, Ketty, additional, and Nestle, Frank O., additional

Published
2011
Full Text
View/download PDF

43. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients.

Author

Saraceno, Rosita, Camplone, Germana, D'Agostino, Magda, De Simone, Clara, Di Cesare, Antonella, Filosa, Giorgio, Frascione, Pasquale, Gabellini, Massimo, Lunghi, Franco, Mazzotta, Annamaria, Peris, Ketty, Scotto Di Luzio, Genoveffa, Calvieri, Stefano, Simonacci, Marco, and Chimenti, Sergio

Subjects
DRUG efficacy, PSORIASIS treatment, SCALP, DISEASES, DISEASE relapse, HEALTH of patients
Abstract

Background: Previous studies showed the efficacy of a formulation containing calcipotriol and betamethasone dipropionate for the treatment of psoriasis. Objective: To investigate maintenance strategies of a formulation containing calcipotriol (50 µg/g) and betamethasone dipropionate (0.5 mg/g) for the treatment of scalp psoriasis. Materials and methods: Nine-hundred and four patients were screened and randomised on a 1:1 basis in two groups: maintenance of two applications per week (group A) versus on-demand therapy (group B). Clinical evaluation was performed at weeks 0, 2, 4, 8 and 12. Results: Eight-hundred and eighty-five patients were randomised: 441 in group A and 444 in group B. From week 2, both groups showed a significant clinical improvement compared with baseline; at weeks 8 and 12, group A demonstrated a higher clinical response compared with group B ( p < 0.05). This difference was statistically significant (OR 0.47, 95% CI 0.37, 0.60). Conclusions: The maintenance of twice-weekly application versus on-demand treatment of calcipotriol/betamethasone dipropionate gel is more effective and is associated with a lower rate of relapse. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

44. A Role for Th17 Cells in the Immunopathogenesis of Atopic Dermatitis?

Author

Di Cesare, Antonella, Di Meglio, Paola, and Nestle, Frank O.

Subjects
*ATOPIC dermatitis, *TH2 cells, *T cells, *SKIN inflammation, *DERMATOLOGY, *SKIN diseases
Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease. Both epidermal barrier dysfunction and immunodysregulation are suggested to influence the pathogenesis of AD. AD has been considered a paradigmatic T helper cell (Th) 2-mediated disease, with a switch to a Th1 cell environment during the chronic phase of the disease. Previously unreported findings now suggest a possible role for Th17 cells as well.Journal of Investigative Dermatology (2008) 128, 2569–2571. doi:10.1038/jid.2008.283 [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

45. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.

Author

Rosi, Elia, Pescitelli, Leonardo, Ricceri, Federica, Di Cesare, Antonella, Novelli, Andrea, Pimpinelli, Nicola, and Prignano, Francesca

Subjects
HIDRADENITIS suppurativa, CLINDAMYCIN, PHYSICIANS, ALTERNATIVE medicine
Abstract

The rifampicin (RF)–clindamycin (CL) combination is recommended as first line therapy in moderate to severe Hidradenitis Suppurativa (HS) by European S1 guidelines. Although prolonged use of RF should be discouraged, there are currently few alternatives to this combination therapy. The aim of the present study was to assess retrospectively the efficacy of oral CL monotherapy in patients diagnosed with HS. In the period January 2017–May 2018, 31 HS patients who received a 300 mg b.i.d. oral dose of CL were studied retrospectively. Efficacy of the treatment was evaluated by comparing the main HS severity scores (Sartorius score modified by Revuz, Hidradenitis Suppurativa Physician Global Assessment [HS‐PGA] and International Hidradenitis Suppurativa Severity Score System [IHS4]) before (W0) and after (W12) CL oral therapy. CL efficacy was demonstrated by the extreme and significant reduction of all three disease severity parameters during the 12‐week period (p ≤ .01). There was also a statistically significant change in the mean visual analogue scale for pain. The present study demonstrates the efficacy of oral CL monotherapy as RF‐sparing regimen alternative to RF–CL combination in a selected group of patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

46. Italian guidelines in diagnosis and treatment of alopecia areata

Author

Marta Muscianese, Giuseppe Monfrecola, Alfredo De Rossi, Stefano Astorino, Valentina Garelli, Francesco Lacarrubba, Annunziata Dattola, Giuseppe Micali, Andrea D'Arino, Alessandro Federico, Simone Garcovich, Luca Stingeni, Oriana Simonetti, Federico Bardazzi, Norma Cameli, Francesca Magri, Stefano Piaserico, Marta Carlesimo, Elena Marinello, Victor Desmond Mandel, Antonella Di Cesare, Katharina Hansel, Stefano Caccavale, Roberto D'Ovidio, Emi Dika, Annamaria Offidani, Donato Di Nunno, Flavia Pigliacelli, Lucia Villa, Cosimo Misciali, Teodora R Stan, Graziana Amendolagine, Colombina Vincenzi, Viviana Lora, Niccolò Rivetti, Maria Beatrice de Felici del Giudice, Maria Caterina Fortuna, Marina Talamonti, Claudio Feliciani, Cristina Guerriero, Alessandro Borghi, Francesca Bruni, Elisabetta Fulgione, Gabriella Fabbrocini, Andrea Carugno, Maria Carmela Annunziata, Paola Monari, Francesco Tassone, Gemma Caro, Maria C Arisi, Piergiacomo Calzavara-Pinton, Matteo Megna, Annalisa Patrizi, Graziella Babino, Bianca Maria Piraccini, Stefano Calvieri, Anna Belloni Fortina, Manuela Papini, Gloria Orlando, Stefania Barruscotti, Michele Cardone, Aurora Alessandrini, Iria Neri, Rosa Coppola, Michelangelo La Placa, Marco Galluzzo, Michela Starace, A Rossi, M Muscianese, BM Piraccini, M Starace, M Carlesimo, VD Mandel, A Alessandrini, S Calvieri, G Caro, A D’arino, A Federico, F Magri, F Pigliacelli, G Amendolagine, MC Annunziata, MC Arisi, G Babino, F Bardazzi, S Barruscotti, A Belloni Fortina, A Borghi, F Bruni, S Caccavale, P Calzavara Pinton, N Cameli, A Carugno, R Coppola, A Dattola, MB De Felici Del Giudice, A Di Cesare, E Dika, R D’ovidio, G Fabbrocini, C Feliciani, E Fulgione, M Galluzzo, S Garcovich, V Garelli, C Guerriro, K Hansel, M La Placa, F Lacarrubba, V Lora, E Marinello, M Megna, G Micali, C Misciali, G Monfrecola, I Neri, A Offidani, G Orlando, M Papini, A Patrizi, S Piaserico, N Rivetti, O Simonetti, TR Stan, L Stingeni, M Talamonti, F Tassone, L Villa, C Vincenzi, MC Fortuna, Rossi, A, Muscianese, M, Piraccini, B, Starace, M, Carlesimo, M, Mandel, V, Alessandrini, A, Calvieri, S, Caro, G, D'Arino, A, Federico, A, Magri, F, Pigliacelli, F, Amendolagine, G, Annunziata, M, Arisi, M, Astorino, S, Babino, G, Bardazzi, F, Barruscotti, S, Belloni Fortina, A, Borghi, A, Bruni, F, Caccavale, S, Calzavara-Pinton, P, Cameli, N, Cardone, M, Carugno, A, Coppola, R, Dattola, A, De Felici Del Giudice, M, Di Cesare, A, Dika, E, Dinunno, D, D'Ovidio, R, Fabbrocini, G, Feliciani, C, Fulgione, E, Galluzzo, M, Garcovich, S, Garelli, V, Guerriero, C, Hansel, K, La Placa, M, Lacarrubba, F, Lora, V, Marinello, E, Megna, M, Micali, G, Misciali, C, Monari, P, Monfrecola, G, Neri, I, Offidani, A, Orlando, G, Papini, M, Patrizi, A, Piaserico, S, Rivetti, N, Simonetti, O, Stan, T, Stingeni, L, Talamonti, M, Tassone, F, Villa, L, Vincenzi, C, Fortuna, M, Rossi, Alfredo, Muscianese, Marta, Piraccini, Bianca M, Starace, Michela, Carlesimo, Marta, Mandel, Victor D, Alessandrini, Aurora, Calvieri, Stefano, Caro, Gemma, D'Arino, Andrea, Federico, Alessandro, Magri, Francesca, Pigliacelli, Flavia, Amendolagine, Graziana, Annunziata, Maria C, Arisi, Maria Chiara, Babino, Graziella, Bardazzi, Federico, Barruscotti, Sefania, Belloni Fortina, Anna, Borghi, Alessandro, Bruni, Francesca, Caccavale, Stefano, Calzavara Pinton, Piergiacomo, Cameli, Norma, Carugno, Andrea, Coppola, Rosa, Dattola, Annunziata, De Felici Del Giudice, Maria B, Di Cesare, Antonella, Dika, Emi, D'Ovidio, Roberto, Fabbrocini, Gabriella, Feliciani, Claudio, Fulgione, Elisabetta, Galluzzo, Marco, Garcovich, Simone, Garelli, Valentina, Guerriro, Cristina, Hansel, Katharina, La Placa, Michelangelo, Lacarrubba, Francesco, Lora, Viviana, Marinello, Elena, Megna, Matteo, Micali, Giuseppe, Misciali, Cosimo, Monfrecola, Giuseppe, Neri, Iria, Offidani, Annamaria, Orlando, Gloria, Papini, Manuela, Patrizi, Annalisa, Piaserico, Stefano, Rivetti, Niccolo', Simonetti, Oriana, Stan, Teodora R, Stingeni, Luca, Talamonti, Maria, Tassone, Francesco, Villa, Lucia, Vincenzi, Colombina, Fortuna, Maria C, Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., Alessandrini, A., Calvieri, S., Caro, G., D'Arino, A., Federico, A., Magri, F., Pigliacelli, F., Amendolagine, G., Annunziata, M. C., Arisi, M. C., Astorino, S., Babino, G., Bardazzi, F., Barruscotti, S., Belloni Fortina, A., Borghi, A., Bruni, F., Caccavale, S., Calzavara-Pinton, P., Cameli, N., Cardone, M., Carugno, A., Coppola, R., Dattola, A., De Felici Del Giudice, M. B., Di Cesare, A., Dika, E., Dinunno, D., D'Ovidio, R., Fabbrocini, G., Feliciani, C., Fulgione, E., Galluzzo, M., Garcovich, S., Garelli, V., Guerriero, C., Hansel, K., La Placa, M., Lacarrubba, F., Lora, V., Marinello, E., Megna, M., Micali, G., Misciali, C., Monari, P., Monfrecola, G., Neri, I., Offidani, A., Orlando, G., Papini, M., Patrizi, A., Piaserico, S., Rivetti, N., Simonetti, O., Stan, T. R., Stingeni, L., Talamonti, M., Tassone, F., Villa, L., Vincenzi, C., and Fortuna, M. C.

Subjects
medicine.medical_specialty, corticosteroid, Alopecia Areata, MEDLINE, Socio-culturale, Alopecia areata, Autoimmunity, Guideline, Autoimmune Diseases, Evidence-Based Medicine, Hair Follicle, Italy, Alopecia areata, Autoimmunity, Dermatology, Disease, Minoxidil, Guideline, Autoimmune Disease, Autoimmune Diseases, Food and drug administration, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Settore MED/35, Evidence-Based Medicine, Hair Follicle, Humans, Italy, alopecia areata, autoimmunity, guideline, autoimmune diseases, evidence-based medicine, hair follicle, humans, italy, Medicine, topical immunotherapy, integumentary system, business.industry, trichoscopy, Evidence-based medicine, medicine.disease, Trichoscopy, Clinical trial, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Human, medicine.drug
Abstract

Alopecia Areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration (FDA). The Italian Study Group for Cutaneous Annexial Disease of the Italian Society of dermatology (SIDeMaST) proposes these Italian guidelines for diagnosis and treatment of Alopecia Areata deeming useful for the daily management of the disease. This article summarizes evidence-based treatment associated with expert-based recommendations.

Published
2019

47. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines

Author

Cozzani, Emanuele, Marzano, Angelo V, Caproni, Marzia, Feliciani, Claudio, Calzavara-Pinton, Piergiacomo, Alaibac, M, Antiga, E, Arisi, M, Assalve, D, Atzori, L, Babino, G, Balato, A, Balato, N, Barbagallo, T, Belloni Fortina, A, Berardesca, E, Berti, E, Borghi, A, Brazzelli, V, Brumana, Mb, Brusati, C, Caccavale, S, Caldarola, G, Calzavara-Pinton, P, Campanati, A, Caposiena Caro RD, Caproni, M, Coati, I, Conti, A, Costanzo, A, Cozzani, E, Dattola, A, De Simone, C, Di Cesare, A, Di Lernia, V, Di Zenzo GM, Fania, L, Filosa, G, Filotico, R, Fusano, M, Gerarda Galluccio, A, Ganzetti, G, Gisondi, P, Guarneri, F, Hansel, K, Javor, S, La Placa, M, Liberati, G, Lora, V, Marzano, Av, Merlo, G, Nasca, Mr, Nigro, A, Noal, C, Offidani, A, Papini, M, Parodi, A, Patrizi, A, Peserico, A, Piaserico, S, Prignano, F, Quaglino, P, Rossi, M, Satta, R, Schena, D, Sena, P, Simonetti, O, Stan, Tr, Stingeni, L, Talamonti, M, Tavecchio, S, Tognetti, L, Vascellaro, A, Vassallo, C, Venturini, M, Zampetti, A, Zanca, A., Cozzani, Emanuele, Marzano, Angelo V., Caproni, Marzia, Feliciani, Claudio, Calzavara-Pinton, Piergiacomo, Alaibac, Mauro, Antiga, Emiliano, Arisi, Mariachiara, Assalve, Danilo, Atzori, Laura, Babino, Graziella, Balato, Anna, Balato, Nicola, Barbagallo, Tania, Fortina, Anna Belloni, Berardesca, Enzo, Berti, Emilio, Borghi, Alessandro, Brazzelli, Valeria, Brumana, Marta B., Brusati, Carlo, Caccavale, Stefano, Caldarola, Giacomo, Campanati, Anna, Caro, Raffaele D. Caposiena, Coati, Ilaria, Conti, Andrea, Costanzo, Antonio, Dattola, Annunziata, De Simone, Clara, Di Cesare, Antonella, Di Lernia, Vito, Di Zenzo, Giovanni M., Fania, Luca, Filosa, Giorgio, Filotico, Raffaele, Fusano, Marta, Galluccio, Antonia Gerarda, Ganzetti, Giulia, Gisondi, Paolo, Guarneri, Fabrizio, Hansel, Katharina, Javor, Sanja, Laplaca, Michelangelo, Liberati, Giulia, Lora, Viviana, Merlo, Giulia, Nasca, Maria R., Nigro, Anna, Noal, Cecilia, Offidani, Annamaria, Papini, Manuela, Parodi, Aurora, Patrizi, Annalisa, Peserico, Andrea, Piaserico, Stefano, Prignano, Francesca, Quaglino, Pietro, Rossi, Mariateresa, Satta, Rosanna, Schena, Donatella, Sena, Paolo, Simonetti, Oriana, Stan, Teodora R., Stingeni, Luca, Talamonti, Marina, Tavecchio, Simona, Tognetti, Linda, Vascellaro, Annalisa, Vassallo, Camilla, Venturini, Marina, Zampetti, Anna, Zanca, Arianna, and La placa, Michelangelo

Subjects
Pemphigoid, Disease, Guideline, 030207 dermatology & venereal diseases, Pruritu, 0302 clinical medicine, Quality of life, Pemphigoid, Bullous, skin and connective tissue diseases, Evidence-Based Medicine, integumentary system, Bullous, Rare diseases, Bullous lesions, Infectious Diseases, Italy, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Bullou, Bullous pemphigoid, Human, medicine.medical_specialty, Venereology, Consensus, Socio-culturale, Consensu, Dermatology, Aged, Humans, Pruritus, Quality of Life, 2708, 03 medical and health sciences, Pemphigoid, Bullou, Settore MED/35, medicine, business.industry, Evidence-based medicine, medicine.disease, eye diseases, business, Rare disease
Abstract

Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients blister may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions, and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on the quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. This guideline for the treatment of bullous pemphigoid has been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S2 level).

Published
2018

48. Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.

Author

Manzo Margiotta F, Michelucci A, Capalbo E, Ricceri F, Rosi E, Rossari S, Magnano M, Savarese I, Milanesi N, Simoni B, Romanelli M, Rubegni P, DI Cesare A, Panduri S, Pescitelli L, Trovato E, and Prignano F

Subjects
Humans, Retrospective Studies, Antibodies, Monoclonal therapeutic use, Immunoglobulin Class Switching, Psoriasis drug therapy
Published
2024
Full Text
View/download PDF

49. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.

Author

Prignano F, Pescitelli L, Trovato E, DI Cesare A, Cuccia A, Mazzatenta C, Pellegrino M, Marsili F, Castelli A, Brandini L, Niccoli MC, Taviti F, Ricceri F, Panduri S, Buggiani G, Ghilardi A, Rubegni P, Romanelli M, and Pimpinelli N

Subjects
Humans, Biological Factors therapeutic use, Consensus, Interleukin-23 therapeutic use, Quality of Life, Tumor Necrosis Factor Inhibitors therapeutic use, Interleukin-17 immunology, Biological Products therapeutic use, Psoriasis drug therapy
Abstract

Psoriasis is a common chronic skin disease characterized by a worldwide distribution and a natural tendency towards progression. According to the many clinical forms, the extension of the disease and the many comorbidities, almost the 20% of the patients require a systemic treatment. Biologics have greatly changed the ongoing of psoriasis and the quality of life of psoriasis patients. After the anti-TNF-alpha, which were the first biologics in use for psoriasis, the improvement in knowledge of the pathogenetic mechanisms underlying the disease has led to the development of a series of more specific therapies for psoriasis. This "second generation" of biologics includes the interleukin (IL)-12/23 inhibitor ustekinumab, IL-17 inhibitors (secukinumab and ixekizumab), the IL-17 receptor A (IL-17RA) antagonist brodalumab, and the IL-23 inhibitors guselkumab, risankizumab and tildrakizumab. This study represents an update of the Tuscany consensus focused on the use of new drugs, such as anti-IL-17 and anti-IL-23 in moderate-to-severe psoriasis and their correct place in therapy according to specific clinical requests and in full respect of the current financial restrictions.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results